Page 6 - Dennisj Slamon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ribociclib regimen reduces recurrence risk in subset of patients with early breast cancer

The addition of ribociclib to adjuvant endocrine therapy significantly reduced the risk for disease recurrence among patients with hormone receptor-positive, HER2-negative early breast cancer, according to the agent’s manufacturer. Ribociclib (Kisqali, Novartis), a category 1 preferred CDK 4/6 inhibitor, showed consistent benefit regardless of nodal involvement among patients with stage II

Mindy valcarcelDennisj slamonRibociclib kisqali

Novartis Reports Positive Topline Results for NATALEE, Phase 3 Trial of Ribociclib in Early Breast Cancer

Results for this study, involving use of this CDK4/6 inhibitor with endocrine therapy, will be presented at an upcoming scientific meeting and submitted to regulators.

United statesDennisj slamonLos angeles jonsson comprehensive cancer centerTranslational research in oncologyNational comprehensive cancer networkNew england journalTranslational researchBreast cancer

Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast Cancer

The combination of ribociclib and endocrine therapy (ET) significantly reduced the risk of disease recurrence vs standard adjuvant ET in patients with hormone receptor–positive/HER2-negative early breast cancer at risk of recurrence.

United statesDennisj slamonShreeram aradhyeTranslational research in oncologyLos angeles jonsson comprehensive cancer centerUniversity of californiaClinical translational researchData monitoring committeeGlobal drug developmentIndependent data monitoring committeeTranslational researchStandardized definitionsEfficacy end pointsBreast cancerEarly breast cancer

NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis

NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesDennisj slamonCatherine marleLos angeles jonsson comprehensive cancer centerTranslational research in oncologyClinical translational researchUniversity of californiaResearch in oncologyTranslational researchExecutive director

Kisqali offers survival benefit for breast cancer patients, finds study

Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months.

United statesJeff legosDennisj slamonUniversity of californiaClinical translational researchEuropean society of medical oncologyLos angeles jonsson comprehensive cancer centerBreast cancer congressMedical oncologyBreast cancerTranslational researchLos angeles jonsson comprehensive cancerExecutive vice presidentGlobal headHematology development